OpenLobby.EU
Explore

International Plasma and Fractionation Association

IPFA

Mission of IPFA IPFA supports and promotes the activities of not-for-profit organisations around the globe engaged in the collection and fractionation of plasma to enable robust, safe supply and patient access to plasma derived medicines. Through education and collaboration with stakeholders, we advocate for public health values and donor health protection. Vision IPFA’s goal is for plasma to be acknowledged as a strategic resource within public health care systems, underpinned by a safe and reliable contribution from the not-for-profit sector. IPFA will continue to show leadership in this field and bring expertise to reach this goal.

Lobbying Activity

Meeting with Nathalie Colin-Oesterlé (Member of the European Parliament, Rapporteur) and Alliance for Regenerative Medicine

24 Nov 2022 · SoHO regulation

Response to Revision of the Union legislation on blood, tissues and cells

14 Dec 2020

IPFA’s mission is to promote policies which ensure access to safe PDMPs to the patients. In this objective and since 2016, IPFA has alerted the European institutions of the unbalanced supply of plasma for PDMPs from third country, namely the US and called for Strategic independence in plasma for fractionation and PDMPs. The Covid-19 situation has highlighted a weakness to be addressed in the Union’s ambition for an open strategic autonomy. This is underlining the need for timely action. IPFA’s missions/advocacy also covers the non-exploitation of donors, ensuring protection from financial dependency, donor safety and promotion of donor health. Careful Donor Acceptance Criteria and ethical conditions of incentives for donations are the basis for ensuring this protection, defined in a common European framework. We should not consider this directive in isolation but ensure consistency with other relevant SoHO legislation. IPFA comments relate to the regulation of Plasma for fractionation, either recovered plasma or plasmapheresis plasma (also called source plasma), as both should be addressed together whenever the use is intended for manufacturing (fractionation) purpose. See attached full document
Read full response